Merck and Afrigen Biologics have signed an MoU for mRNA platform technology to enhance regional manufacturing capacity. Credit: © 2017 – 2024 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved.

Germany-based Merck KGaA’s Life Science business sector has signed a non-binding memorandum of understanding (MoU) with Afrigen Biologics to advance the development of an mRNA vaccine technology platform.

The deal bolsters its mRNA platform manufacturing expertise, scales up manufacturing, optimises processes and offers troubleshooting capabilities.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Merck will contribute to the centre of excellence and training initiatives of Afrigen.

These efforts are designed to build capacity in low and middle-income countries (LMICs) for producing mRNA vaccines and therapeutics.

Bert de Vet, Merck Life Science business sector commercial Europe, Middle East and Africa process solutions head, stated: “Leveraging our comprehensive chemical portfolio and custom production capabilities, we offer cutting-edge experience for mRNA manufacturing, ensuring a seamless journey from research to production.

See Also:

“Our alliance with Afrigen for mRNA technology platform development echoes our commitment to fostering equitable access to life-saving therapies for global health.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The partnership is part of a broader mRNA technology transfer programme led jointly by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).

This programme is centred around a South African consortium tasked with establishing and validating an mRNA manufacturing platform at a central site called the ‘hub’. This technology platform will then be transferred to partners.

The Afrigen-based mRNA vaccine tech transfer programme is set to provide a comprehensive transfer of knowledge, enabling the existing 15 recipient manufacturers to manufacture and provide mRNA vaccines at scale.

The initiative will support clinical development, national/regional marketing authorisation and WHO prequalification, and ensure a viable supply to meet the vaccine demand locally and regionally.

Afrigen Biologics CEO Petro Terblanche said: “The platform at Afrigen provides access to mRNA technology for 15 partners in LMICs and straddles the entire vaccine value chain from research and development (R&D) to good manufacturing practices manufacturing.

“Following the launch of the programme in 2021, we have successfully developed mRNA vaccine technology R&D and production capabilities.”

In June 2024, Merck KGaA announced a €62m ($66.6m) investment to construct a new quality control facility for its Life Science business at Darmstadt in Germany.

mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena)  is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.